As the impact of India’s second wave of coronavirus is said to be worse on young people, especially children, many parents and paediatricians in the country have been especially concerned.
The approval of Bharat Biotech’s inactivated virus-based COVID-19 vaccine Covaxin for clinical trials on children above age two is seen as a watershed moment by many health experts.
Bharat Biotech may reportedly start clinical trials on children from June. Currently, pregnant and lactating mothers, special populations, and children are being denied vaccination.
